GlassScriptPhysician profile
Aida J Lopez
NPI 1497717854
$16,162.44
in general payments reported to CMS, 2019-2025
57 companies · $3,221 in 2025
The $3,221 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,856 · 2022: $2,665 · 2023: $3,238 · 2024: $4,183 · 2025: $3,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,673 · Long Term Medical Supply Or Device Loan: $1,448 · Education: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,673.40 |
| Long Term Medical Supply Or Device Loan | $1,447.87 |
| Education | $520.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,745.88 | 2021-2025 | |
| Pfizer INC. | $1,337.04 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,022.89 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $903.50 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $872.18 | 2021-2025 | Jakafi |
| Genzyme Corporation | $840.34 | 2021-2025 | |
| Seagen INC. | $649.14 | 2021-2023 | Tukysa, Tivdak, Adcetris |
| Astrazeneca Pharmaceuticals LP | $631.87 | 2021-2025 | Tagrisso, Calquence |
| Daiichi Sankyo INC. | $584.10 | 2021-2025 | Enhertu |
| Eisai INC. | $582.40 | 2021-2025 | |
| Amgen INC. | $405.15 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $385.91 | 2021-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $365.73 | 2022-2025 | |
| Exelixis INC. | $280.75 | 2021-2024 | Cabometyx |
| Celgene Corporation | $271.27 | 2021-2025 | Pomalyst, Reblozyl |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $259.45 | 2022-2024 | Monoferric |
| Adaptive Biotechnologies Corporation | $248.76 | 2022-2025 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $229.81 | 2021-2025 | Opdivo, Reblozyl |
| Jazz Pharmaceuticals INC. | $224.18 | 2021-2025 | |
| Puma Biotechnology, INC. | $206.33 | 2021-2024 | |
| Sobi, INC | $202.12 | 2022-2024 | |
| Emd Serono, INC. | $195.41 | 2023-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $189.40 | 2021-2024 | Onivyde, Somatuline Depot |
| Mirati Therapeutics, INC. | $184.18 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $183.07 | 2021-2025 | Xospata, Padcev, Vyloy |
| Abbvie INC. | $172.18 | 2023-2025 | |
| Genentech USA, INC. | $163.05 | 2023-2024 | Venclexta, Polivy, Columvi |
| Tersera Therapeutics LLC | $143.39 | 2023-2025 | Zoladex |
| Alexion Pharmaceuticals, INC. | $138.11 | 2021-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $135.49 | 2024-2025 | |
| Janssen Biotech, INC. | $133.96 | 2024-2025 | Erleada, Talvey, Akeega |
| Regeneron Healthcare Solutions, INC. | $131.38 | 2022-2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $121.90 | 2024-2025 | Zejula, Jemperli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.65 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $102.31 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Beigene USA, INC. | $84.56 | 2023-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $68.07 | 2021-2023 | Epkinly, Imbruvica |
| Dova Pharmaceuticals | $60.97 | 2021 | |
| Taiho Oncology, INC. | $52.53 | 2023-2025 | |
| Pharmaessentia USA Corporation | $44.80 | 2025 | Besremi |
| Foundation Medicine, INC. | $35.69 | 2022 | |
| Global Blood Therapeutics, INC. | $32.38 | 2021 | |
| Dendreon Pharmaceuticals LLC | $30.16 | 2021 | |
| Stemline Therapeutics INC. | $29.61 | 2025 | Orserdu |
| Aurinia Pharma U.S., INC. | $29.21 | 2025 | Lupkynis |
| Deciphera Pharmaceuticals INC. | $28.11 | 2025 | Tgct, Qinlock |
| Caris Mpi, INC. | $27.14 | 2025 | Mi Cancer Seek |
| Tg Therapeutics, INC. | $25.86 | 2022 | |
| Acceleron Pharma, INC. | $24.61 | 2021 | |
| Array Biopharma INC | $23.37 | 2024 | Lorbrena, Braftovi, Mektovi |
| Amneal Pharmaceuticals LLC | $23.07 | 2023 | Avastin, Neupogen, Neulasta |
| Agios Pharmaceuticals, INC. | $20.75 | 2025 | Pyrukynd |
| Sirtex Medical INC | $20.22 | 2022 | |
| Beone Medicines USA, INC. | $19.51 | 2025 | Brukinsa |
| Immunogen, INC. | $18.99 | 2023 | Elahere |
| Myovant Sciences INC. | $15.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.